Damaging effects of gliadin on three-dimensional cell culture model

Figure 1 Volumes of MCTSs treated with PT-gliadin.

Figure 2 Viability test of MCTSs after treatment with different doses of digested gliadin (A) and lactate dehydrogenase (LDH) activity after gliadin treatment (B).

Figure 3 Content of reduced GSH (A) and GSH-related enzyme activity (B) in MCTSs treated with PT-gliadin.

Figure 4 Microscopic analysis of MCTSs treated with digested gliadin or untreated. (A and B) Untreated and gliadin-treated MCTSs with cytoplasmatic vacuoles, (C and D) images of untreated and treated MCTSs, and (E) no holes and blebs on untreated controls, (F) holes and blebs on the surface of treated MCTSs.